Community-acquired Pneumonia Clinical Trial
Official title:
Clinical Failure and Cardiovascular Events in Hospitalized Patients With Community-Acquired Pneumonia: The Failcap Study
Although failure and mortality are the most relevant outcomes in patients with
Community-acquired Pneumonia (CAP), there is little discussion in the literature on their
incidence and etiology. A pathophysiological approach has been recently developed and used
to evaluate clinical failure in CAP patients. Clinical failure has been analyzed as related
versus unrelated to CAP, considering the role that the pulmonary infection and the
inflammatory response played in the development of this outcome. Cardiac events were
identified as triggers of clinical failures in a significant percentage of CAP patients. The
development of cardiovascular events have been also identified in CAP patients both on
admission to the hospital and during hospitalization. However, data on this topic belong to
studies evaluating only selected populations of veteran patients with CAP. Understanding
clinical failure, as well as cardiovascular events in hospitalized patients with CAP would
be useful in order to prevent complications during the hospitalization, to develop new
treatment modalities and, thus, to improve outcomes.
The objectives of this international, multicenter, observational, prospective cohort study
will be: 1) To define incidence, timing, etiology and risk factors of clinical failure,
related vs. unrelated to CAP, in hospitalized patients with CAP; 2) To define incidence,
timing, and risk factors for cardiovascular events either on hospital admission or during
hospitalization in hospitalized patients with CAP.Consecutive adult patients hospitalized
for CAP in acute care hospitals in Europe and US will be enrolled. Daily clinical
evaluations. Demographics, history, clinical, radiological, and antibiotic therapy data will
be recorded, as well as serum, urinary and respiratory samples will be collected both on
admission and during hospitalization from consenting individuals. Patients will be
classified as having a CAP-related versus CAP-unrelated failure, according to a
pathophysiological classification. Patients will be also classified as having or not a
cardiovascular event either on admission or during hospitalization.The following outcomes
will be measured:
1) Incidence, timing, etiology and risk factors of clinical failure related vs. unrelated to
CAP; 2) Incidence, timing and risk factors of cardiovascular events; 3)time to clinical
stability, length of hospital stay, mortality at hospital discharge, and mortality at 30 and
180 days.
n/a
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05722938 -
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
|
Phase 3 | |
Terminated |
NCT04972318 -
Two Different Ventilatory Strategies in Acute Respiratory Distress Syndrome Due to Community-acquired Pneumonia
|
N/A | |
Recruiting |
NCT06065618 -
Characteristics of Hospitalized Patients With Community-acquired Pneumonia
|
||
Not yet recruiting |
NCT03675178 -
Clinical Study of Anerning Particle for the Treatment of Childhood Community-acquired Pneumonia
|
Phase 4 | |
Not yet recruiting |
NCT04166110 -
Antibiotic Therapy In Respiratory Tract Infections
|
N/A | |
Completed |
NCT02380352 -
Short-course Antimicrobial Therapy for Paediatric Respiratory Infections
|
Phase 4 | |
Completed |
NCT01671280 -
Drug Use Investigation Of Azithromycin IV For Community-Acquired Pneumonia Or Pelvic Inflammatory Disease (Regulatory Post Marketing Commitment Plan)
|
N/A | |
Completed |
NCT02555852 -
Proton Pump Inhibitors and Risk of Community-acquired Pneumonia
|
N/A | |
Recruiting |
NCT00752947 -
Efficacy and Safety Trial to Assess Moxifloxacin in Treating Community-Acquired Pneumonia (CAP) With Aspiration Factors
|
Phase 4 | |
Completed |
NCT00140023 -
Azithromycin Microspheres in Patients With Low Risk Community Acquired Pneumonia
|
Phase 3 | |
Recruiting |
NCT04089787 -
Shortened Antibiotic Treatment of 5 Days in Community-Acquired Pneumonia
|
Phase 4 | |
Completed |
NCT05356494 -
Postural Drainage and PEP Technique in Community Acquired Pneumonia
|
N/A | |
Completed |
NCT05133752 -
Oral Nemonoxacin in Treating Elderly Patients With CAP
|
Phase 4 | |
Not yet recruiting |
NCT06291012 -
Stopping Pneumonia Antibiotherapy Regimen Early
|
Phase 4 | |
Recruiting |
NCT05002192 -
A Retrospective, Real-world Study of ELP Used in the Expectorant Treatment of Community-acquired Pneumonia
|
||
Completed |
NCT03452826 -
Combined Use of a Respiratory Broad Panel mPCR and Procalcitonin to Reduce Duration of Antibiotics Exposure in Patients With Severe Community-Acquired Pneumonia
|
N/A | |
Terminated |
NCT04071041 -
Effect of Albumin Administration in Hypoalbuminemic Hospitalized Patients With Community-acquired Pneumonia.
|
Phase 3 | |
Completed |
NCT03474991 -
KIDS-STEP_Betamethasone Therapy in Hospitalised Children With CAP
|
Phase 3 | |
Completed |
NCT01683487 -
Delayed Antibiotic Treatment in Community-acquired Pneumococcal Pneumonia.
|
Phase 4 | |
Completed |
NCT01723644 -
Clinical Reassessment Versus Procalcitonin in Order to Shorten Antibiotic Duration in Community-acquired Pneumonia
|
N/A |